{"entity":{"id":"nct05338931","kind":"trial","name":"Safety, Tolerability, and Efficacy of AT101 in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma","aka":[],"tldr":"A phase 1/2 trial of AT101 in hodgkin lymphoma and non-hodgkin lymphoma, run by AbClon, now recruiting.","summary":"Safety, Tolerability, and Efficacy of AT101 in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma is a phase 1/2 interventional study registered as NCT05338931 by AbClon, with 82 participants planned, started 2022-03-15 and due to reach its primary completion in 2030-03-15. Interventions recorded: AT101(Anti-CD19 Chimeric Antigen Receptor T cell). Conditions listed: B-cell Non Hodgkin Lymphoma. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05338931","url":"https://clinicaltrials.gov/study/NCT05338931"}],"tags":["ctgov-ingest"],"related":[],"cancers":["hodgkin-lymphoma","non-hodgkin-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":["at101"],"companies":["abclon"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05338931","phase":"1/2","setting":"An Open-label, Single-arm, Multi-center, Phase I/II Study to Evaluate the Safety, Tolerability, and Efficacy of AT101 (Anti-CD19 Chimeric Antigen Receptor T Cell) in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma","sponsor":"AbClon","participation":[{"nct":"NCT05338931","source":"https://clinicaltrials.gov/study/NCT05338931","fetchedAt":"2026-10-07T16:53:40.482Z","studySha256":"636bf013284e79977ca8d57dc2a29c8b98efb9074f79c0dfde3207010a7132e1","overallStatus":"RECRUITING","lastUpdatePosted":"2022-05-26","leadSponsor":"AbClon","collaboratorCount":0,"minimumAge":"19 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":82,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":1,"countries":["South Korea"]}],"started":"2022-03-15","startedType":"actual","enrolled":82,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05338931/","neighbours":{"cancer":[{"id":"hodgkin-lymphoma","kind":"cancer","name":"Hodgkin lymphoma","route":"/cancers/hodgkin-lymphoma/"},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}],"drug":[{"id":"at101","kind":"drug","name":"AT101","route":"/drugs/at101/"}],"company":[{"id":"abclon","kind":"company","name":"AbClon","route":"/companies/abclon/"}]}}